Clinical Scorecard: What's Next for Prenatal Screening?

At a Glance

Key Highlights

• NIPT screens for fetal genetic abnormalities using cffDNA in maternal blood, but positive results require confirmation by invasive testing.
• The review identifies low fetal fraction, difficulty distinguishing fetal from maternal DNA, and differences between placental and fetal genotype as biological barriers.
• Most circulating cffDNA is approximately 143 base pairs, but circular, approximately 50-base-pair, and longer fragments have also been reported.
• The mechanism by which cffDNA circulates remains unresolved; the authors report that direct evidence for apoptotic extracellular vesicles as its release route is lacking.
• The authors identify determining cffDNA’s cellular origin and how much circulating DNA is associated with extracellular particles as research priorities before NIPT can reliably progress toward comprehensive genetic diagnosis.

Guideline-Based Recommendations

Diagnosis

• The article says positive NIPT results require confirmation by invasive diagnostic testing, such as chorionic villus sampling or amniocentesis.

Management

• The review describes research approaches, not clinical management recommendations; it proposes investigating immunoaffinity enrichment and microfluidics to isolate selected DNA-containing particles or longer fetal DNA fragments.

Monitoring & Follow-up

• The article does not provide clinical monitoring recommendations.

Risks

• The lead author states that 47% of high-risk results in the cited account were false alarms, creating stress and an unnecessary invasive procedure.
• The review notes that placental mosaicism can cause cffDNA to differ from the true fetal genotype and complicate result interpretation.

Patient & Prescribing Data

The article describes NIPT as screening for fetal genetic abnormalities from around 10 weeks’ gestation; it does not provide prescribing or treatment data.

NIPT is a screening test, not a confirmed diagnosis. The article says positive results require follow-up diagnostic testing; the review discusses possible future improvements to fetal DNA enrichment and test performance.

Clinical Best Practices

• The article states that positive NIPT results require confirmation by invasive diagnostic testing.
• The review notes that DNA described as fetal in maternal blood is predominantly placental and may not always reflect the fetal genotype.
• The review reports that cffDNA release and circulation mechanisms remain uncertain.

Related Resources & Content